A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-26. Anything still debated is marked as such rather than presented as settled.
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
=== Mislabelled door swipe data === During the first trial, door swipe records were used to establish Letby's presence on the neonatal unit at the time of various incidents. In August 2024, the Crown Prosecution Service confirmed that swipe data for one of the unit's doors had been mislabelled, with entries and exits reversed. The CPS did not confirm whether data for other doors had been correctly labelled. Cheshire Police reviewed the use of the incorrect data and concluded that it had been relied upon in evidence relating to nine infants, although it played a central role only in the case of Child K, for whom Letby was not convicted at the first trial. A second door to the unit did not record entries or exits, meaning that swipe card data could not account for all movements into and out of the unit.
Vasopressin is regulated by AVP gene expression which is managed by major clock controlled genes. In this circadian circuit known as the transcription-translation feedback loop (TTFL), Per2 protein accumulates and is phosphorylated by CK1E. Per2 subsequently inhibits the transcription factors Clock and BMAL1 in order to reduce Per2 protein levels in the cell. At the same time, Per2 also inhibits the transcription factors for the AVP gene in order to regulate its expression, the expression of vasopressin, and other AVP gene products. Many factors influence the secretion of vasopressin:
In early December 2025, Colombian president Petro's personal lawyer filed a complaint with the Inter-American Commission on Human Rights (IACHR) against Hegseth on behalf of Carranza's family. According to CNN, the sister of the Ecuadorian survivor of the 16 October strike, repatriated to Ecuador, "claim[ed] to know nothing of her brother's alleged involvement with drug trafficking and instead portrayed him as a desperate father trying to provide for his six kids". The Ecuadorian had been convicted and deported from the US in 2020 for drug smuggling. The Ecuadorian attorney general's office stated that no crime reports had been filed against him with their institution, so absent evidence for detaining him, the subject was released. The other survivor of the 16 October strike, repatriated to Colombia, was hospitalized upon arrival with moderate injuries, including a skull fracture. Petro and Armando Benedetti, Colombian Minister of the Interior, said at the time he was repatriated the survivor would be "prosecuted according to the law, because he is allegedly a criminal who was trafficking drugs". However, because the incident occurred in international waters, outside Colombian territory, he would only be prosecuted if he voluntarily spoke and incriminated himself. He was released on 6 November with no charges.
== Biosynthesis == Its complete biosynthetic pathway includes glycolysis, the tricarboxylic acid (TCA) or citric acid cycle (Krebs cycle), and the aspartate metabolic pathway. It forms by two reductions of aspartic acid via the intermediacy of aspartate semialdehyde. Specifically, the enzyme homoserine dehydrogenase, in association with NADPH, catalyzes a reversible reaction that interconverts L-aspartate-4-semialdehyde to L-homoserine. Homoserine kinase and homoserine O-succinyltransferase convert homoserine to phosphohomoserine and O-succinyl homoserine, respectively. Homoserine is produced from aspartate via the intermediate aspartate-4-semialdehyde, which is produced from β-phosphoaspartate. By the action of homoserine dehydrogenases, the semialdehyde is converted to homoserine.
Sources: en.wikipedia.org
Vortioxetine, sold under the brand names Trintellix (in the US) and Brintellix (in Europe) among others, is an antidepressant medication of the serotonin modulator and stimulator (SMS) class used in the treatment of major depressive disorder. Its effectiveness is viewed as similar to that of other antidepressants. It is taken orally. Common side effects include nausea, dry mouth, diarrhea, constipation, vomiting (3-6% of people), and sexual dysfunction. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and SIADH. A withdrawal syndrome may occur if the medication is abruptly stopped or the dose is decreased. Use during pregnancy and breastfeeding is not generally recommended. Vortioxetine's mechanism of action is not entirely understood, but is believed to be related to increasing serotonin levels and possibly interacting with certain serotonin receptors. It was approved for medical use in the United States and in the European Union in 2013. In 2020, it was the 243rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.
=== Asylum fees and immigration === The law establishes a $100 annual fee to apply for asylum, down from $1,000 in the House bill, a $550 fee to apply for employment authorization for asylum seekers and migrants on humanitarian parole or temporary protected status, and a $500 fee to apply for temporary protected status. It also increases the fees for non-immigrant visas to $250.
== Privacy and security concerns == Privacy concerns have been brought up regarding the app. TikTok's privacy policy lists that the app collects usage information, IP addresses, a user's mobile carrier, unique device identifiers, keystroke patterns, and location data, among other data. Other information collected includes users inferred interests based on the content they view as well as content created by users. TikTok is also able to track information about web users even if they are not users of the TikTok app. It collects information such as IP address, online browsing habits and web search history. TikTok can share data with its corporate group, including ByteDance. The company says that it employs access control and approval process overseen by a US-based team. In June 2021, TikTok updated its privacy policy to include potential collection of biometric data, including "faceprints and voiceprints", for special effects and other purposes. The terms said that user authorization would be requested if local law demands such. Experts considered them to be "vague" and their implications "problematic" for the United States due to the country's general lack of robust data privacy laws. In a November 2022 update to its European privacy policy, TikTok stated that its global corporate group employees from China and other countries could gain remote access to the user information of accounts from Europe based on "demonstrated need".
=== Category:EC 5.1 (racemases and epimerases) === Category:EC 5.1.1 Amino-acid racemase: Phenylalanine racemase (ATP-hydrolysing) Serine racemase Category:EC 5.1.2 Mandelate racemase Category:EC 5.1.3 UDP-glucose 4-epimerase Category:EC 5.1.99 Methylmalonyl CoA epimerase
== Termination == Termination occurs when one of the three termination codons moves into the A site. These codons are not recognized by any tRNAs. Instead, they are recognized by proteins called release factors, namely RF1 (recognizing the UAA and UAG stop codons) or RF2 (recognizing the UAA and UGA stop codons). These factors trigger the hydrolysis of the ester bond in peptidyl-tRNA and the release of the newly synthesized protein from the ribosome. A third release factor RF-3 catalyzes the release of RF-1 and RF-2 at the end of the termination process.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.